Novel Platform for Antigen Delivery to Dendritic Cells for Immunotherapy

0558734 - ÚMCH 2023 CH eng M - Část monografie knihy
Dölen, Y. - Gileadi, U. - Chen, J.-L. - Valente, M. - Creemers, J. H. A. - van Dinther, E. A. W. - van Riessen, N. K. - Jäger, Eliezer - Hrubý, Martin - Cerundolo, V. - Diken, M. - Figdor, C. G. - de Vries, I. J. M.
PLGA nanoparticles co-encapsulating NY-ESO-1 peptides and IMM60 induce robust CD8 and CD4 T Cell and B cell responses.
Novel Platform for Antigen Delivery to Dendritic Cells for Immunotherapy. Lausanne: Frontiers Media SA, 2022 - (Affandi, A.; Plantinga, M.; Caminschi, I.), s. 21-35. ISBN 978-2-88976-427-3
GRANT EU: European Commission(XE) 686089 - PRECIOUS
Institucionální podpora: RVO:61389013
Klíčová slova: NY-ESO-1 * iNKT cell * B cell epitope
Obor OECD: Polymer science
https://www.frontiersin.org/research-topics/14870/novel-platform-for-antigen-delivery-to-dendritic-cells-for-immunotherapy#articles

Tumor-specific neoantigens can be highly immunogenic, but their identification for each patient and the production of personalized cancer vaccines can be time-consuming and prohibitively expensive. In contrast, tumor-associated antigens are widely expressed and suitable as an off the shelf immunotherapy. Here, we developed a PLGA-based nanoparticle vaccine that contains both the immunogenic cancer germline antigen NY-ESO-1 and an α-GalCer analog IMM60, as a novel iNKT cell agonist and dendritic cell transactivator. Three peptide sequences (85–111, 117–143, and 157–165) derived from immunodominant regions of NY-ESO-1 were selected. These peptides have a wide HLA coverage and were efficiently processed and presented by dendritic cells via various HLA subtypes. Co-delivery of IMM60 enhanced CD4 and CD8 T cell responses and antibody levels against NY-ESO-1 in vivo. Moreover, the nanoparticles have negligible systemic toxicity in high doses, and they could be produced according to GMP guidelines. Together, we demonstrated the feasibility of producing a PLGA-based nanovaccine containing immunogenic peptides and an iNKT cell agonist, that is activating DCs to induce antigen-specific T cell responses.
Trvalý link: https://hdl.handle.net/11104/0335287